Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vivalis SA and Intercell AG Complete Merger of Equals and Create Valneva SE; Plan to Launch EUR 40 Million Rights Issue
Valneva SE (Valneva) announced the completion of the merger of equals between Vivalis SA and Intercell AG, as a result of which the Company was created. Valneva is a European biotech company focused on vaccines and antibodies. Its ordinary shares start trading on the regulated market of NYSE Euronext in Paris under the ticker symbol VLA.PA and on the Prime Market segment of the Vienna Stock Exchange under the ticker symbol VLA. Valneva preferred shares will start trading on the regulated market of NYSE Euronext in Paris under ticker symbol VLApr.PA and on the unregulated Third Market Segment of the Vienna Stock Exchange under the ticker symbol VLAP. Goldman Sachs International and Societe Generale Corporate and Investment Banking are acting as advisors on the merger. The Company also announced on December 16, 2012, that it plans to launch, subject to market conditions and to the approval from the French Autorite des marches financiers on the Prospectus which will be prepared for this purpose, the rights issue of an envisaged amount of EUR 40 million.
Latest Developments for Valneva SE
- Valneva SE confirms FY 2014 outlook guidance
- Valneva SE announces first ever marketing approval in Europe for vaccine produced in EB66 cell line
- Valneva SE announces first marketing authorization for human vaccine produced in EB66 cell line
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
- Share this
- Digg this